Medicus Pharma Reports Positive Topline Results for D-MNA Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Should l Buy MDCX?
Source: Newsfilter
- Clinical Trial Design: The SKNJCT-003 clinical study was a randomized, double-blind, placebo-controlled multi-center trial enrolling 90 patients with basal cell carcinoma, demonstrating a 73% clinical clearance rate at Day 57 in the high-dose group, significantly outperforming the placebo group.
- Efficacy Data Analysis: The efficacy data at Days 29 and 57 showed that the 200μg D-MNA group achieved clinical and histological clearance rates of 73% and 40%, respectively, indicating sustained biological activity over time and supporting further development.
- FDA Meeting Preparation: The company plans to hold an EOP2 meeting with the FDA in the first half of 2026, and based on the positive clinical results, it expects to accelerate readiness for partnerships with pharmaceutical companies, enhancing its market competitiveness.
- Strategic Development Focus: Medicus is focused on building clinical data packages to advance select programs into late-stage development and seeks to establish strategic partnerships with pharmaceutical companies to achieve commercialization goals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDCX
Wall Street analysts forecast MDCX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.380
Low
12.00
Averages
12.00
High
12.00
Current: 1.380
Low
12.00
Averages
12.00
High
12.00
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Decline as Kroger Reports Mixed Q4 Results
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points, down 0.67% to 48,411.44, indicating weakened market sentiment that could impact investor confidence.
- Kroger Earnings: Kroger reported mixed fourth-quarter results, with adjusted EPS of $1.28 exceeding market expectations of $1.20, yet sales of $34.725 billion fell short of the $35.064 billion forecast, highlighting challenges in sales growth.
- Future Guidance: The company anticipates FY2026 adjusted EPS between $5.10 and $5.30, slightly below the $5.29 estimate, which may affect investor confidence regarding Kroger's future growth prospects.
- Sector Movements: Energy shares rose by 1.5%, while healthcare stocks dipped by 1.3%, reflecting varied market reactions across sectors that could influence investor asset allocation strategies.
See More
Medicus Pharma Shares Surge on Phase 2 Trial Data Release
- Clinical Trial Results: Medicus Pharma released topline data from its SKNJCT-003 Phase 2 clinical trial, indicating a 73% clinical clearance rate and a 40% histological clearance rate for the 200µg dose cohort, which supports an end-of-phase meeting with the FDA anticipated in the first half of 2026.
- Market Reaction: Despite shares surging to $1.61 during Thursday's premarket session, they ultimately fell by 21.01% to $1.09, reflecting market concerns about the company's long-term performance, especially as the stock approaches its 52-week low.
- Technical Analysis: Currently, the stock trades 8.70% above its 20-day simple moving average but is 12.5% below its 100-day SMA, indicating short-term strength but longer-term challenges, prompting investors to watch for potential shifts in momentum.
- Future Plans: The company aims to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations, with the goal of advancing its development programs and pursuing strategic partnerships.
See More
Medicus Pharma Reports Positive Topline Results for D-MNA Clinical Trial
- Clinical Trial Design: The SKNJCT-003 clinical study was a randomized, double-blind, placebo-controlled multi-center trial enrolling 90 patients with basal cell carcinoma, demonstrating a 73% clinical clearance rate at Day 57 in the high-dose group, significantly outperforming the placebo group.
- Efficacy Data Analysis: The efficacy data at Days 29 and 57 showed that the 200μg D-MNA group achieved clinical and histological clearance rates of 73% and 40%, respectively, indicating sustained biological activity over time and supporting further development.
- FDA Meeting Preparation: The company plans to hold an EOP2 meeting with the FDA in the first half of 2026, and based on the positive clinical results, it expects to accelerate readiness for partnerships with pharmaceutical companies, enhancing its market competitiveness.
- Strategic Development Focus: Medicus is focused on building clinical data packages to advance select programs into late-stage development and seeks to establish strategic partnerships with pharmaceutical companies to achieve commercialization goals.
See More
Medicus Pharma Receives FDA Clearance for Teverelix Study
- FDA Approval for Clinical Study: Medicus Pharma has received FDA clearance to initiate a Phase 2b dose-optimization study for Teverelix, enrolling 40 men with advanced prostate cancer suitable for androgen deprivation therapy, indicating strategic progress in the precision medicine sector.
- Study Design Details: The trial will implement a loading dose of 540 mg, followed by 360 mg every six weeks, aiming for over 90% confirmation of medical castration by Day 29, which, if successful, will provide a new treatment option for advanced prostate cancer patients and fill a significant market gap.
- Cardiovascular Safety Focus: Teverelix's mechanism avoids the testosterone surge associated with GnRH agonists, potentially reducing cardiovascular risks, particularly for patients with pre-existing cardiovascular conditions, which is expected to attract a patient demographic with high safety concerns.
- Significant Market Potential: With approximately 300,000 to 500,000 men in the U.S. living with advanced prostate cancer, representing an annual market opportunity exceeding $4 billion, successful clinical trials will lay a foundation for Medicus Pharma's long-term growth and enhance its competitiveness in the biopharmaceutical industry.
See More
Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, at the Nasdaq MarketSite in Times Square, New York, marking its one-year anniversary as a publicly listed company and highlighting its steady growth in the capital markets.
- Significant Clinical Progress: The company is advancing two key therapeutic assets, SkinJect targeting basal cell carcinoma with an estimated $2 billion market opportunity, and Teverelix for high cardiovascular risk prostate cancer patients, representing a combined market potential of $6 billion, showcasing its strategic positioning in precision medicine.
- Clinical Trial Advancements: Medicus has successfully enrolled 90 patients in the Phase 2 clinical trial for SkinJect in the U.S., with topline results expected in Q1 2026, which will lay the groundwork for future partnership opportunities and enhance the company's influence in the biopharmaceutical sector.
- Strategic Collaboration Expansion: The company has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving capital-efficient clinical development, expected to support an upcoming Teverelix clinical study planned for 2026.
See More
Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, in Times Square, New York, marking its one-year anniversary as a public company, reflecting its stability and growth potential in the capital markets.
- Clinical Development Progress: The company is focused on advancing key therapeutic assets like SkinJect and Teverelix, with SkinJect targeting a $2 billion market opportunity for basal cell carcinoma and Teverelix addressing high cardiovascular risk in prostate cancer patients, collectively representing a $6 billion commercial value.
- Clinical Trial Results: The Phase 2 trial for SkinJect is nearing completion of patient enrollment, with topline results expected in Q1 2026, potentially creating partnership opportunities and further enhancing the company's influence in the biotech sector.
- Strategic Collaboration and Expansion: The partnership with the Gorlin Syndrome Alliance aims to provide expanded access to SkinJect for patients with multiple basal cell carcinomas, expected to gather crucial safety and tolerability data, thereby strengthening the company's market position in rare diseases.
See More
U.S. Stocks Decline as Kroger Reports Mixed Q4 Results
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points, down 0.67% to 48,411.44, indicating weakened market sentiment that could impact investor confidence.
- Kroger Earnings: Kroger reported mixed fourth-quarter results, with adjusted EPS of $1.28 exceeding market expectations of $1.20, yet sales of $34.725 billion fell short of the $35.064 billion forecast, highlighting challenges in sales growth.
- Future Guidance: The company anticipates FY2026 adjusted EPS between $5.10 and $5.30, slightly below the $5.29 estimate, which may affect investor confidence regarding Kroger's future growth prospects.
- Sector Movements: Energy shares rose by 1.5%, while healthcare stocks dipped by 1.3%, reflecting varied market reactions across sectors that could influence investor asset allocation strategies.
See More
Medicus Pharma Shares Surge on Phase 2 Trial Data Release
- Clinical Trial Results: Medicus Pharma released topline data from its SKNJCT-003 Phase 2 clinical trial, indicating a 73% clinical clearance rate and a 40% histological clearance rate for the 200µg dose cohort, which supports an end-of-phase meeting with the FDA anticipated in the first half of 2026.
- Market Reaction: Despite shares surging to $1.61 during Thursday's premarket session, they ultimately fell by 21.01% to $1.09, reflecting market concerns about the company's long-term performance, especially as the stock approaches its 52-week low.
- Technical Analysis: Currently, the stock trades 8.70% above its 20-day simple moving average but is 12.5% below its 100-day SMA, indicating short-term strength but longer-term challenges, prompting investors to watch for potential shifts in momentum.
- Future Plans: The company aims to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations, with the goal of advancing its development programs and pursuing strategic partnerships.
See More
Medicus Pharma Reports Positive Topline Results for D-MNA Clinical Trial
- Clinical Trial Design: The SKNJCT-003 clinical study was a randomized, double-blind, placebo-controlled multi-center trial enrolling 90 patients with basal cell carcinoma, demonstrating a 73% clinical clearance rate at Day 57 in the high-dose group, significantly outperforming the placebo group.
- Efficacy Data Analysis: The efficacy data at Days 29 and 57 showed that the 200μg D-MNA group achieved clinical and histological clearance rates of 73% and 40%, respectively, indicating sustained biological activity over time and supporting further development.
- FDA Meeting Preparation: The company plans to hold an EOP2 meeting with the FDA in the first half of 2026, and based on the positive clinical results, it expects to accelerate readiness for partnerships with pharmaceutical companies, enhancing its market competitiveness.
- Strategic Development Focus: Medicus is focused on building clinical data packages to advance select programs into late-stage development and seeks to establish strategic partnerships with pharmaceutical companies to achieve commercialization goals.
See More
Medicus Pharma Receives FDA Clearance for Teverelix Study
- FDA Approval for Clinical Study: Medicus Pharma has received FDA clearance to initiate a Phase 2b dose-optimization study for Teverelix, enrolling 40 men with advanced prostate cancer suitable for androgen deprivation therapy, indicating strategic progress in the precision medicine sector.
- Study Design Details: The trial will implement a loading dose of 540 mg, followed by 360 mg every six weeks, aiming for over 90% confirmation of medical castration by Day 29, which, if successful, will provide a new treatment option for advanced prostate cancer patients and fill a significant market gap.
- Cardiovascular Safety Focus: Teverelix's mechanism avoids the testosterone surge associated with GnRH agonists, potentially reducing cardiovascular risks, particularly for patients with pre-existing cardiovascular conditions, which is expected to attract a patient demographic with high safety concerns.
- Significant Market Potential: With approximately 300,000 to 500,000 men in the U.S. living with advanced prostate cancer, representing an annual market opportunity exceeding $4 billion, successful clinical trials will lay a foundation for Medicus Pharma's long-term growth and enhance its competitiveness in the biopharmaceutical industry.
See More
Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, at the Nasdaq MarketSite in Times Square, New York, marking its one-year anniversary as a publicly listed company and highlighting its steady growth in the capital markets.
- Significant Clinical Progress: The company is advancing two key therapeutic assets, SkinJect targeting basal cell carcinoma with an estimated $2 billion market opportunity, and Teverelix for high cardiovascular risk prostate cancer patients, representing a combined market potential of $6 billion, showcasing its strategic positioning in precision medicine.
- Clinical Trial Advancements: Medicus has successfully enrolled 90 patients in the Phase 2 clinical trial for SkinJect in the U.S., with topline results expected in Q1 2026, which will lay the groundwork for future partnership opportunities and enhance the company's influence in the biopharmaceutical sector.
- Strategic Collaboration Expansion: The company has entered a non-binding letter of intent with Reliant AI Inc. to develop an AI-driven clinical data analytics platform aimed at improving capital-efficient clinical development, expected to support an upcoming Teverelix clinical study planned for 2026.
See More
Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary
- Anniversary Celebration: Medicus Pharma will ring the Nasdaq Opening Bell on January 22, 2026, in Times Square, New York, marking its one-year anniversary as a public company, reflecting its stability and growth potential in the capital markets.
- Clinical Development Progress: The company is focused on advancing key therapeutic assets like SkinJect and Teverelix, with SkinJect targeting a $2 billion market opportunity for basal cell carcinoma and Teverelix addressing high cardiovascular risk in prostate cancer patients, collectively representing a $6 billion commercial value.
- Clinical Trial Results: The Phase 2 trial for SkinJect is nearing completion of patient enrollment, with topline results expected in Q1 2026, potentially creating partnership opportunities and further enhancing the company's influence in the biotech sector.
- Strategic Collaboration and Expansion: The partnership with the Gorlin Syndrome Alliance aims to provide expanded access to SkinJect for patients with multiple basal cell carcinomas, expected to gather crucial safety and tolerability data, thereby strengthening the company's market position in rare diseases.
See More
